Protalix

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

Role: lead

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

Role: lead

Extension Study of PRX-102 for up to 60 Months

Role: lead

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Role: lead

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Role: lead

Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients

Role: lead

Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks

Role: lead

Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion

Role: collaborator

Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease

Role: lead

Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®

Role: lead

Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis

Role: lead

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

Role: lead

Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers

Role: lead

Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers

Role: lead

Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Role: lead

An Exploratory Phase 1 Microdose Study of PRX-105

Role: lead

Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

Role: lead